Dexpramipexole dihydrochloride Catalog No.:M9926-2 Ginsenoside Rb2 enhances the anti-inflammatory

Ginsenoside Rb2 enhances the anti-inflammatory effect of ω-3 fatty acid in LPS-stimulated RAW264

AG14361 markedly enhances NSC 362856 activity against LoVo xenografts and delays tumor growth when combined with NSC 362856

A-438079 partially but significantly prevented the 6-OHDA-induced depletion of striatal DA stores

2-oxazol-5-yl)-5-[4-(propane-2-sulfonyl)phenyl]pyrazin-2-amine

Dexpramipexole dihydrochloride Catalog No.:M9926-2 Ginsenoside Rb2 enhances the anti-inflammatoryDexpramipexole, also known as KNS 760704 and (R) Pramipexole, is under development for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrigs disease. The drug failed to show efficacy in terms of function or survival in a Phase III study of patients with ALS. Dexpramipexole is a low molecular weight, water soluble, orally bioavailable, renally excreted compound with linear pharmacokinetics, and has been shown to be well